Elucida Oncology, Inc. Elucida Oncology, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Platform
    • Pipeline
    • Publications
  • Careers
  • News & Media
    • Overview
    • Press Releases
    • Media
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Media

News & Media

  • Overview
  • Press Releases
  • Media
  • Presentations
  • Email Alerts

Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023

Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 3, 2022

Elucida Oncology to Present at Two Upcoming Conferences

Jun 3, 2022

Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting

Jun 1, 2022

Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference

May 6, 2022

Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting

Apr 4, 2022

Elucida Oncology to Present at Two Upcoming Scientific Conferences

Mar 3, 2022

Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones

Jan 5, 2022

Elucida Oncology to Present at Two Upcoming Investor Conferences

Jan 5, 2022

Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference

Dec 15, 2021
  • 1
  • 2
  • 3
© 2023 Elucida Oncology, Inc. All Rights Reserved. The Elucida Oncology™ name and Logo and Target or Clear™ are trademarks of Elucida Oncology, Inc.
Privacy Policy Disclaimer Terms of Use Sitemap